GlassScriptPhysician profile
Ann Michele Hill
NPI 1679507727
$56,105.18
in general payments reported to CMS, 2019-2025
24 companies · $18K in 2025
The $18K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $381 · 2021: $473 · 2022: $770 · 2023: $16K · 2024: $20K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $3,986 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,550.00 |
| Food and Beverage | $3,986.33 |
| Education | $144.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $50,469.79 | 2019-2025 | Aklief, Nemluvio, Dysport |
| Abbvie INC. | $1,413.52 | 2019-2025 | |
| Janssen Biotech, INC. | $641.89 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $458.44 | 2021-2025 | Adbry |
| Pfizer INC. | $338.98 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $317.01 | 2019-2025 | |
| Dermavant Sciences, INC. | $302.55 | 2022-2024 | Vtama |
| Ucb, INC. | $278.98 | 2023-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $277.04 | 2020-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $276.32 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $240.95 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $172.69 | 2019-2024 | Siliq, Targretin |
| Dermira, INC. | $146.91 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $138.96 | 2024-2025 | Sotyktu |
| Allergan, INC. | $137.39 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $106.84 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $95.38 | 2019 | |
| Amgen INC. | $73.46 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $63.64 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $59.54 | 2020-2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.96 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $31.04 | 2020-2022 | |
| Genentech USA, INC. | $16.14 | 2023 | Erivedge |
| Almirall LLC | $14.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.